The results presented herein represent our continued study based on the modification of phenolic functionality in molecules originated from natural sources by acylation. A small focused library of nineteen eugenyl esters, with four of which are new compounds, is reported. All compounds were subjected to in vitro antimicrobial testing. In silico studies were carried out calculating physico-chemical, pharmacokinetic and toxicological properties, providing more data as additional guidance for further research.
Introduction
Natural products, especially those derived from plants, represent an excellent source of new bioactive compounds since their structures may be used as natural pharmacophores enabling structural derivatization. 1 Phenylpropenes belong to a vast family of compounds called phenylpropanoids that are biosynthesized in plants from the amino acids phenylalanine and tyrosine via shikimate pathway. 2 Phenylpropenes, such as eugenol, isoeugenol, chavicol and anethole are biosynthesized by flowering plants as defense compounds against animals and microorganisms. 3 Because of the antimicrobial properties of phenylpropenes, as well as their pleasant aromas and flavors, since ancient times humans have used plant materials containing such compounds to preserve and flavor their food (cloves, allspice, black pepper, anise, fennel; all of these containing significant amounts of phenylpropenes) and as medicinal agents. 3 Eugenol (4-allyl-2-methoxyphenol) is naturally occurring in essential oils of variety of plants belonging to Lamiaceae, Lauraceae, Myrtaceae and Myristicaceae families. It is one of the major constituents of clove (Syzygium aromaticum (L.) Merrill & Perry, Myrtaceae) oil and is largely used both in foods and as flavouring agent. 4, 5 Eugenol and its close analogues have several proven biological activities [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] which make it useful in pharmaceutical production. Additionally, eugenol has been described as an agent with dual effect: antioxidant and pro-oxidant, postulating the existence of beneficial properties in both prevention of cancer formation and in cancer treatment. 17 According to previous in vitro and in vivo studies eugenol might function as a tumor suppressor in most cancer types inspected. [17] [18] [19] [20] The activity of eugenol against microorganisms is also well known. 21, 22 The mechanisms of antimicrobial action have been documented in both bacteria and fungi. 21, [23] [24] [25] According to a review discussing mechanisms of antimicrobial action of eugenol and essential oils containing eugenol, two main uses of eugenol are particularly indicated: against food-decaying microorganisms and Lazarević et al.: Synthesis, Antimicrobial Activity ... against bacteria causing oral clinical conditions. 21 In a review published by Freires et al. 26 it was concluded that due to its promising antimicrobial activity against streptococci, eugenol should be considered as an anti-cariogenic agent worth of further clinical testing. The mode of action of eugenol against microbials has been thoroughly investigated and reviewed by Marchese et al. 21 In this paper a systematic presentation of the mechanisms against bacteria and fungi known so far is given. Compounds obtained by derivatisation of eugenol have also been reported as antimicrobial agents. 1, [27] [28] [29] [30] So far, the most frequently investigated eugenol derivatives in bioassays are glycosides [27] [28] [29] [30] and esters. [31] [32] [33] Like eugenol, eugenyl esters can also represent compounds of promising biological properties. Several papers on isolation and/or synthesis and biological activity of eugenyl esters have reported wide range of activities: antioxidant, 9, 11, 13, 34 anticancer, 35 larvicidal, 37 anti-leishmaniasis. 38 On the other hand, little data exists on antimicrobial activity, reporting only few compounds involved with respect to the total number synthesized. Antimicrobial assays evaluated antibacterial activity of eugenyl esters of acetic, 3-methylbutanoic, pentanoic and benzoic acids, [31] [32] [33] but no data related to antifungal activity of such derivatives was reported.
The diverse pharmacological activity of eugenol and eugenyl esters, scarce results on antibacterial and no results on antifungal activity of ester derivatives, have determined the aim of our study. By making a modification of a phenolic functionality in eugenol, we have obtained a series of ester compounds (3a-s), performed their structural characterization, in vitro antimicrobial testing and in silico calculation of physico-chemical, pharmacokinetic and toxicological properties. An important contribution of this study is the synthesis of four new compounds (3l, 3n, 3p and 3r), followed by the results obtained in antibacterial together with the first results ever obtained in an antifungal assay, and by in silico calculations. All together represent an important aspect to guide further research.
Materials and Methods

1. Chemicals Used
All the reagents, standards and solvents used were of analytical reagent grade. Unless specified otherwise, all chemicals were purchased from Merck (Darmstadt, Germany).
General Synthetic Procedures
Acetyl, benzoyl and palmitoyl chloride (2a, 2r, 2s) were purchased from Sigma-Aldrich. For the preparation of acyl chlorides 2b-p, 2r and of eugenyl esters (Table 1 , entries 3a-s) methods from the literature [39] [40] [41] [42] were utilized and general procedures for the synthesis as reported in our previously published paper was followed. 43 Scheme 1 represents the synthesis of eugenyl esters.
The obtained esters of eugenol 3a-s were purified by column chromatography, stationary phase Silica Gel 60 (70-230 mesh), mobile phase (hexane/diethyl ether, gradient 9:1 to 6:4). For yields see Table 1 . For solid compounds 3q, 3r and 3s melting points were determined in a Stuart Scientific SMP3 apparatus and are uncorrected.
Eugenyl Acetate (3a)
Chromatographic purification gave yellowish oil. C 12 20 .71 (C-12). Physical and spectroscopic data were in accordance with those reported. 37, 38 Eugenyl Propanoate (3b)
Chromatographic purification gave yellowish oil. 27 .39 (C-12), 9.23 (C-13). Physical and spectroscopic data were in accordance with those reported. 37, 38 Eugenyl Butanoate (3c)
Chromatographic purification gave colorless oil. C 14 13 . Physical and spectroscopic data were in accordance with those reported. 33, 44 Eugenyl Pentanoate (3e)
Chromatographic purification gave colorless oil. 
Eugenyl Hexanoate (3g)
Chromatographic purification gave colorless oil. 10H, bm, H-14-H-18) , 0.83-1.06 (3H, m, H-19); 13 
Eugenyl Dodecanaote (3m)
Chromatographic purification gave colorless oil. H-14-H-21) , 0.92 (3H, t, J = 6.6 Hz, H-22); 13 C-19), 29.10 (C-14) , 25 .10 (C-13), 22 .72 (C-21), 14.14 (C-22). Physical and spectroscopic data were in accordance with those reported. 18, 38 Eugenyl Tridecanaote (3n)
Chromatographic purification gave yellowish oil. 
Eugenyl Tetradecanoate (3o)
Chromatographic purification gave yellowish oil. 25 .12 (C-13), 22 .74 (C-23), 14.14 (C-24). Physical and spectroscopic data were in accordance with those reported. 18 
Eugenyl Pentadecanoate (3p)
Chromatographic purification gave colorless oil. C 25 , H-12), 1.78 (2H, m, H-13), 1.27-1.50 (18H, bm,  H-14-H-24) , 0.97-0.88 (3H, m, H-25); 13 
Eugenyl Benzoate (3s)
Chromatographic purification gave white solid. 1H, m, H-9), 5.12-5.18 (2H, m, H-10),  3.83 (3H, s, H-7 
3. Identification of Synthetized Compounds
3. 1. GC-MS Analysis
MS spectra of samples of the synthesized compounds were recorded on a 7890/7000B GC/MS/MS triple quadrupole system (Agilent Technologies, USA, equipped with a Combi PAL auto sampler). The fused silica capillary column HP-5MS (5% phenylmethylsiloxane, 30 m × 0.25 mm, film thickness 0.25 μm, Agilent Technologies, Palo Alto, CA, USA) was used. The injector, source and interface operated at 250, 230 and 300 °C, respectively. The temperature program: from 60 for 5 min isothermal to 300 °C at a heating rate of 8 °C/min and on 300 °C for 5 min isothermal. The solutions in hexane were injected in split ratio 10:1. The carrier gas was helium with a flow of 1.0 mL/min. Post run: back flash for 1.89 min, at 280 °C, with helium at 50 psi. MS conditions were as follows: ionization voltage of 70 eV, acquisition mass range 50-650, scan time 0.32 s. Semi-quantitative analysis was carried out directly from peak areas in the GC profile.
Linear retention indices (RI) were determined based on the retention times of C 8 -C 40 alkanes run on HP-5MS column using the above mentioned temperature programme. 45 
3. NMR Analysis
NMR spectra were registered on a Bruker AVANCE 500 spectrometer equipped with a 5 mm broadband reverse probe with field z-gradient operating at 500.13 and 125.76 MHz for 1 H and 13 C, respectively. All NMR spectra were recorded at 298 K in CDCl 3 (isotopic enrichment 99.95%) solution. Chemical shifts are reported on the δ (ppm) scale and are relative to residual CHCl 3 signals (7.24 for 1 H and 77.0 ppm, central line, for 13 C spectra respectively), and scalar coupling constants are reported in hertz. The experimental error in the measured 1 H-1 H coupling constants was ± 0.5 Hz.
The signals assignment was given by a combination of 1D and 2D COSY and HSQC experiments, using standard Bruker pulse programs. and C. albicans (3d, 3f, 3n, 3n and 3s) being the most sensitive strains on the synthesized derivatives. On the other hand, all three Gram-negative microorganisms tested (E. coli, S. abony and S. typhimurium) were completely resistant to synthesized compounds tested (initial concentration 2 mg/mL).
Four of our samples (3a, 3e, 3f, 3s ) are matching the samples tested in antibacterial assays so far. [29] [30] [31] Eugenyl acetate (3a) was tested in a disc diffusion method on a set of seven Gram-positive and nine Gram-negative bacteria. 30 The results have shown notable antimicrobial effect against all sixteen bacteria tested, with a superior performance when compared to pure eugenol. 30 Even when different methodologies were employed, two crucial and completely opposed observations can be made; our results have shown that derivatives have never exceeded the activity of the parent compound and that all were inactive against Gram-negative bacteria taken into consideration. Eugenyl benzoate (3s) was tested previously in disc diffusion assay against a smaller panel of laboratory controlled bacterial strains (two Gram-positive, two Gram-nagative). 29 Eugenyl pentanoate (3e) and 3-methylbutanoate (3f) were tested against seventeen different bacterial strains (ATTC, clinical or food isolates) and have shown moderate antibacterial potential, with inhibitory values (MIC) ranging from 0.32 to 6.00 mg/mL. 31 No noticeable difference in the susceptibility of Gram-negative and Gram-positive bacteria was observed. 31 For the rest of the synthesized compounds (3b-d, 3g-r) antibacterial results are reported here for the first time. For all compounds synthetized (3a-s) results obtained for antifungal assay are the first ever reported ( Table 2 ).
In silico Study
1. Physico-chemical Properties of the Eugenyl Esters 3a-s
Lipinski's rule of five has been used to evaluate drug likeness and to determine if a pharmacologically or biologically active compound has properties that would make it a likely orally active drug in humans. In our previously published paper we have already summarized factors important for optimal bioavailability of synthesized compounds. 52 According to the physico-chemical properties calculated by Molinspiration software tool, 48 compounds 3a-h and 3s fulfilled all requirements for good oral bioavailability, including m i LogP < 5, n ON < 10, n OHNH < 5, MW < 500, TPSA < 140 Å 2 (< 60 Å 2 ), and n rotb < 10 (Suplementary data, Table S1 ).
2. Pharmacokinetic Properties of the Eugenyl Esters 3a-s
Absorption properties of compounds 3a-s were predicted by admetSAR 49 (Supplementary data, Table S2 ). Based on the results, all of the studied compounds were predicted as compounds able to pass through blood-brain barrier and penetrate into the central nervous system, as compounds capable of being absorbed by intestine, as well as compounds permeable across Caco-2 cells. Compounds 3g-r were predicted as P-glycoprotein substrates, while compound 3s was predicted as P-glycoprotein inhibitor. None of the studied compounds was predicted as inhibitor of renal organic cation transporter.
Metabolic properties of the eugenyl esters 3a-s were predicted by admetSAR 49 (Supplementary data, Table S3 ). None of the studied compounds was predicted as CYP2C9 and/or CYP2D6 substrate, while 15 compounds (3c, 3e-r) were predicted as CYP3A4 substrate. Regarding CYP450 inhibition, enzyme CYP1A2 might be inhibited by compounds 3c, 3e-s, CYP2C9 by compound 3s, CYP2C19 by compounds 3b, 3c, 3h-s. However, none of the compounds was predicted as CYP2D6 inhibitor. Most of the investigated compounds were predicted to have low CYP 450 inhibitory promiscuity, except compounds 3a, 3d and 3s.
Toxicological Properties of the Eugenyl Esters 3a-s
Using Toxtree prediction tool based on a decision tree approach, 51 we have predicted structural alerts for DNA and protein binding for the studied compounds. Regarding DNA binding alerts, all of the studied compounds were predicted to have the ability to undergo nucleophilic aliphatic substitution (S N 1 reactions) and Michael addition. Among the protein binding alerts, compounds 3a-s were predicted as compounds able to undergo Michael addition and S N 2 reactions; 3a-s were predicted as compounds able to participate in acyl transfer (results given in Supplementary data, Tables S4 and S5) .
Based on the toxicological properties predicted by admetSAR 49 compounds 3a-s have been characterized as weak hERG (human Ether-à-go-go-Related Gene) inhibitors, non-AMES toxic and non-carcinogenic, but highly toxic for fish, Tetrahymena pyriformis and honey bee. Five compounds (3a-c, 3e and 3g) were predicted as ready biodegradable. According to the risk for acute oral toxicity, all of the studied compounds (3a-s) were predicted as Category III, or slightly toxic compounds, with LD 50 values between 500 and 5000 mg/kg. Depending on the median toxic dose (TD 50 ), all compounds were predicted as "non-required" or non-carcinogenic chemicals (Supplementary data, Table S6 ).
Toxicological properties of the studied compounds predicted by DataWarrior 50 indicate that all compounds have high risk for tumorigenic and irritant effects. All compounds were predicted with no risk for mutagenic effects and no risk for reproductive effects (Supplementary data, Table S7 ).
Conclusion
We have synthesized nineteen esters of eugenol, of which four represent new compounds (3l, 3n, 3p and 3r) . All of the compounds were employed in antimicrobial bioassay, with several compounds tested for the first time in antibacterial (3b-d, 3g-r) and all of the compounds (3a-s) ever tested in antifungal activity bioassay. The results have indicated microorganisms' selective susceptibility, with B. subtilis (3d, 3l, 3n-r) , S. aureus (3e and 3f), C. albicans (3d, 3f, 3n, 3r-s) and A. niger (3f, 3s) as the most susceptible ones, with minimal inhibitory or cidal concentrations (MIC/MBC/MFC) never exceeding the range of activity of eugenol as the parent compound. Based on current results and on our previously published ones, 43 having in best case comparable but never greater MIC values than for parent phenolic compound we could not confirm results obtained by previous groups. [29] [30] [31] Our results have shown the importance of free phenolic hydroxyl group in terms of activity against microbials, however more detailed research should be conducted involving also a more complex viewpoint, as for instance, the disclosure of mechanism of action of eugenyl esters on bacteria and fungi.
The results of our in silico study have shown that compounds fulfilling Lipinski's rule of five are 3a-h and 3s and were predicted to have good oral bioavailability. All of the studied compounds were predicted as to be able to pass through blood-brain barrier capable of being absorbed by intestine and permeable across Caco-2 cells. Metabolic properties differ within the studied compounds, depending on whether they act as substrate and/or inhibitor of various CYP450 enzymes. Compounds 3a-s were predicted as weak hERG inhibitors, non-AMES toxic and non-carcinogenic, but highly toxic for fish, T. pyriformis and honey bee. Further, they were predicted as Category III of risk for acute oral toxicity, as well as compounds with high risk for tumorigenic and irritant effects. Finally, they exhibited at least two structural alerts for both DNA and protein binding, indicating their ability to act as a mutagen or a genotoxic.
Taking in consideration predicted in silico properties and estimated drug likeness score, pharmacological and toxicological profile, eugenyl esters might be used as prodrugs of eugenol due to an expected enhanced lipophilicity 53 and passive membrane transport.
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